secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ocugen, Inc. (OCGN)
CIK:        0001372299
Form:       8-K
Filed at:   2023-02-28T23:59:59+00:00
Accession:  0001628280-23-005369
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocugen reports FY2022 net loss per share $0.38; cash runway into Q1 2024; OCU400 enrollment complete
--------------------------------------------------------------------------------

- FY2022 net loss $0.38/share vs $0.30 prior year; Q4 net loss $0.10/share vs $0.07.
- Cash, equivalents, and investments $90.9M as of Dec 31, 2022; estimated runway into Q1 2024.
- OCU400 Phase 1/2 RP enrollment completed; high dose set; Phase 3 targeted end of 2023.
- IND submitted for OCU200 (diabetic macular edema); OCU410/OCU410ST IND planned Q2 2023.
- NeoCart Phase 3 trial design agreed with FDA; start expected H1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372299/000162828023005369/0001628280-23-005369-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372299/000162828023005369/ocgn-20230228.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-005369

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer